Must not have received systemic antineoplastic therapy including radiation therapy within  days of the study enrollment, except hydroxyurea or -mercaptopurine for the purposes of cytoreduction; patients may also have received all-trans retinoic acid (ATRA) if there is an early suspicion of acute promyelocytic leukemia (acute promyelocytic leukemia [APL], M-AML), although if confirmed to have APL these patients will be excluded from the study
Subject has a diagnosis of acute promyelocytic leukemia (APL)
Subject is diagnosed as acute promyelocytic leukemia (APL).
Acute progranulocytic leukemia (APL, M)
Diagnosed with acute promyelocytic leukemia (APL, M)
Acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL); patients with brief exposure to all-trans retinoic acid (ATRA), arsenic trioxide (ATO) or similar product for suspected APL, who later turn out not to have APL, are eligible for the study
Participants that have acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL, M subtype of AML) or patients with a t(:) cytogenetic translocation.
Acute promyelocytic leukemia (APL)
Patients must have histologically or cytologically documented newly diagnosed de novo acute myeloid leukemia (non-acute promyelocytic leukemia [APL]) that has not yet been treated; hydrea and all-trans retinoic acid (ATRA) previous treatments are acceptable
Acute promyelocytic leukemia (APL, M) unless failed regimens that included tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT candidates for stem cell transplantation
APL (acute promyelocytic leukemia) by WHO criteria [AML with t(;)]
Subjects with acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL)
Diagnosed with acute promyelocytic leukemia (APL, M)
Has acute promyelocytic leukemia (APL, FAB M).
Diagnosis of acute promyelocytic leukemia (APL, or AML M subtype).
Acute promyelocytic leukemia (APL)
Patients must have histologically or cytologically documented newly diagnosed acute myeloid leukemia (non-acute promyelocytic leukemia [APL]) that has not yet been treated; hydroxyurea (Hydrea) and tretinoin (ATRA) previous treatments are acceptable
Patients with acute promyelocytic leukemia (APL) are not eligible
Acute promyelocytic leukemia (APL)
Patients with acute promyelocytic leukemia (APL) as diagnosed by morphologic criteria, flow cytometric characteristics, and rapid cytogenetics or FISH or molecular testing
AML, other than acute promyelocytic leukemia (APL), in first or second remission or with minimal residual disease
Subject was diagnosed as acute promyelocytic leukemia (APL).
The patient has a diagnosis of acute promyelocytic leukemia (APL; FAB M).
Diagnosis of acute promyelocytic leukemia (APL)
AML M Acute Promyelocytic Leukemia (APL) or patients with a t(:) cytogenetic translocation.
Acute promyelocytic leukemia (APL)
Subject was diagnosed as acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL, M) unless failed regimens that included tretinoin, arsenic trioxide, anthracyclines and cytarabine and currently NOT candidates for stem cell transplantation
Treatment-related AML or acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL)
Diagnosis of acute promyelocytic leukemia (APL)
Patient has acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL, M)
Acute promyelocytic leukemia (APL)
Patients must have histologically or cytologically confirmed nonacute promyelocytic leukemia (APL) acute myeloid leukemia (AML)
Diagnosis of acute promyelocytic leukemia (APL)
Patients with acute promyelocytic leukemia (APL)
Acute promyelocytic leukemia (APL)
A diagnosis of acute promyelocytic leukemia (APL); the study does not require to rule APL out for every subject; however, if there is clinical suspicion for APL, such diagnosis has to be ruled out before initiation of treatment
Subject was diagnosed as acute promyelocytic leukemia (APL).
Diagnosis of acute promyelocytic leukemia (APL).
Acute promyelocytic leukemia (APL)
Patients with the following diagnoses are not eligible:\r\n* Acute promyelocytic leukemia (APL)\r\n* Down syndrome\r\n* Juvenile myelomonocytic leukemia (JMML)
Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M or WHO classification of APL with translocation, t(;)(q;q), or breakpoint cluster region-Abelson murine leukemia viral oncogene homolog  (BCR-ABL) positive leukemia (ie, chronic myelogenous leukemia in blast crisis); subjects who undergo diagnostic workup for APL and treatment with all-trans retinoic acid (ATRA), but who are found not to have APL, are eligible (treatment with ATRA must be discontinued before starting induction chemotherapy).
Patients must not have acute promyelocytic leukemia (APL) and must not have evidence of t(;)(q;q)
Patients with newly diagnosed AML or acute promyelocytic leukemia (APL)
Subjects with acute promyelocytic leukemia (APL)